Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results
